APYX Apyx Medical Corp

Nasdaq apyxmedical.com


$ 3.91 $ -0.17 (-4.18 %)    

Friday, 14-Nov-2025 15:50:17 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 3.9
$ 3.94
$ 3.90 x 200
$ 3.95 x 200
$ 3.86 - $ 4.03
$ 0.76 - $ 4.44
119,351
na
149.14M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-08-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-09-2024 03-31-2024 10-Q
8 03-21-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-16-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-11-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-17-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-12-2021 06-30-2021 10-Q
19 05-12-2021 03-31-2021 10-Q
20 03-31-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-11-2020 03-31-2020 10-Q
24 03-31-2020 12-31-2019 10-K
25 11-15-2019 09-30-2019 10-Q
26 08-07-2019 06-30-2019 10-Q
27 05-08-2019 03-31-2019 10-Q
28 03-14-2019 12-31-2018 10-K
29 11-02-2018 09-30-2018 10-Q
30 08-01-2018 06-30-2018 10-Q
31 05-15-2018 03-31-2018 10-Q
32 03-13-2018 12-31-2017 10-K
33 11-03-2017 09-30-2017 10-Q
34 08-03-2017 06-30-2017 10-Q
35 05-15-2017 03-31-2017 10-Q
36 03-10-2017 12-31-2016 10-K
37 10-27-2016 09-30-2016 10-Q
38 08-02-2016 06-30-2016 10-Q
39 05-11-2016 03-31-2016 10-Q
40 03-18-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 citizens-upgrades-apyx-medical-to-market-outperform-announces-8-price-target

Citizens analyst David Turkaly upgrades Apyx Medical (NASDAQ:APYX) from Market Perform to Market Outperform and announces $8...

 apyx-medical-raises-fy2025-sales-guidance-from-50000m-52000m-to-50500m-52500m-vs-50001m-est

Apyx Medical (NASDAQ:APYX) raises FY2025 sales outlook from $50.000 million-$52.000 million to $50.500 million-$52.500 million ...

 apyx-medical-q3-eps-005-beats-010-estimate-sales-12877m-beat-12002m-estimate

Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.10) ...

 apyx-medical-submits-fda-510k-for-device-label-expansion-of-ayon-body-contouring-system

Initiated Nationwide Commercial Launch of AYON in SeptemberThe Company is Hosting a Virtual Key Opinion Leader Event to Discuss...

 apyx-medical-launches-renuvion-in-china

Strong clinical interest and early procedures completedEntered into distribution agreement with GlamMoon, a division of BeauCar...

 apyx-medical-affirms-fy2025-sales-guidance-of-4760m-4900m-vs-4803m-est

Apyx Medical (NASDAQ:APYX) affirms FY2025 sales outlook from $47.60 million-$49.00 million to $47.60 million-$49.00 million vs ...

 apyx-medical-q1-eps-010-beats-012-estimate-sales-943m-beat-939m-estimate

Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) ...

 apyx-medical-revises-2025-total-revenue-outlook-from-476m---495m-to-476m---490m-est-48462m

The Company continues to expect operating expenses of less than $40.0 million for the year ended December 31, 2025.

 apyx-medical-q4-2024-gaap-eps-012-beats-015-estimate-sales-1422m-beat-1339m-estimate

Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION